All In Biotech

Drug Trial Radar · NCT01227655

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.

Last checked: Nov 19, 2026Latest source record: Oct 19, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

427

Actual

Start

Mar 2011

Primary completion

Jul 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Bial - Portela C S.A.Industry
Sponsor type
Industry
First posted
Oct 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 83 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year. BIA 9-1067 is currently being developed by BIAL (Portela \& Cª,S.A.) to be used in addition to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising results have been obtained for BIA 9-1067 in previous studies.

Conditions

  • Parkinson's Disease

Interventions

  • BIA 9-1067Drug

    Capsules will be used.

  • PlaceboDrug

    comparator

  • LevodopaDrug

  • CarbidopaDrug

    DOPA decarboxylase inhibitor (DDCI)

  • BenserazideDrug

    DOPA decarboxylase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)Time frame: 14-15 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bial - Portela & Cª, S.A.

    S. Mamede Do Coronado, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.